CN107970257A - A kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation - Google Patents
A kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation Download PDFInfo
- Publication number
- CN107970257A CN107970257A CN201711402613.8A CN201711402613A CN107970257A CN 107970257 A CN107970257 A CN 107970257A CN 201711402613 A CN201711402613 A CN 201711402613A CN 107970257 A CN107970257 A CN 107970257A
- Authority
- CN
- China
- Prior art keywords
- parts
- ear
- pharmaceutical composition
- preparation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation, and in parts by weight, the ear pharmaceutical composition component includes：90~98 parts of isopropanol, 2~8 parts of glycerine, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin；The ear pharmaceutical composition, ear can make moisture evaporation in ear play bacteriostasis at the same time with pharmaceutical preparation, and safe ready is quick, reduce tinnitus, dysacousis, otalgia, otitis externa, the generation of otitis media diseases.
Description
Technical field
The present invention relates to technical field of pharmaceuticals, and in particular to a kind of ear pharmaceutical composition, preparation method and applications with
Ear pharmaceutical preparation.
Background technology
With the raising of people's standard of living, life style also gradually variation, can inevitably run into showing for the interior water inlet of ear
As such as swimming, having a bath, other activities in hair washing daily life.Water inlet such as not cleaning in time, may result in tinnitus in ear,
The relevant diseases such as dysacousis, otalgia, otitis externa, tympanitis.The country temporarily uses highest at present without Related product, people at present
Several removal ears in the method for moisture include：Finger picks one's ears, and picks up the ears to hop, cotton swab water suction.Picked one's ears with finger, easily
Dig broken duct and cause infection；Hop pick up the ears it cannot be guaranteed that moisture removes completely in ear；The inconvenient also bad palm of cotton swab water suction
Control dynamics and depth, easily damage eardrum.
The content of the invention
In view of this, this application provides a kind of ear pharmaceutical composition, preparation method and applications and ear medicine system
Agent；The ear pharmaceutical composition, ear can make moisture evaporation in ear play bacteriostasis at the same time with pharmaceutical preparation, and safe ready is fast
Victory, reduces tinnitus, dysacousis, otalgia, otitis externa, the generation of otitis media diseases.
To solve above technical problem, technical solution provided by the invention is a kind of ear pharmaceutical composition, with parts by weight
Meter, the ear pharmaceutical composition component include：90~98 parts of isopropanol, 2~8 parts of glycerine, 0.04~0.07 part of boric acid, allantois
0.002~0.005 part of element.
Preferably, in parts by weight, the ear pharmaceutical composition includes：92~95 parts of isopropanol, 4~6 parts of glycerine, boron
0.04~0.07 part of acid, 0.002~0.005 part of allantoin.
Preferably, in parts by weight, the ear pharmaceutical composition includes：93.5 parts of isopropanol, 5 parts of glycerine, boric acid
0.04~0.07 part, 0.002~0.005 part of allantoin.
Preferably, in parts by weight, the ear pharmaceutical composition further includes：1.4~1.6 parts of water.
Preferably, in parts by weight, the ear pharmaceutical composition further includes：1.5 parts of water.
Present invention also offers a kind of preparation method of ear pharmaceutical composition, comprise the following steps：Take ear medicine group
Polymer component mixes, to obtain the final product；In parts by weight, the ear pharmaceutical composition component includes：90~98 parts of isopropanol, glycerine 2
~8 parts, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.
Preferably, in parts by weight, the ear pharmaceutical composition further includes：1.4~1.6 parts of water.
Preferably, the preparation method comprises the following steps：
In parts by weight, 0.04~0.07 part of boric acid is taken, 1.4~1.6 parts with water of 0.002~0.005 part of allantoin mixes,
Obtain mixed solution；
By 90~98 parts of the mixed solution and isopropanol, 2~8 parts of glycerine mixes, to obtain the final product.
Preferably, the preparation method comprises the following steps：
In parts by weight, 0.04~0.07 part of boric acid is taken, 1.4~1.6 parts with water of 0.002~0.005 part of allantoin mixes,
Obtain mixed solution；
By 92~95 parts of the mixed solution and isopropanol, 4~6 parts of glycerine mixes, to obtain the final product.
Preferably, the preparation method comprises the following steps：
In parts by weight, 0.04~0.07 part of boric acid is taken, 1.5 parts with water of 0.002~0.005 part of allantoin is mixed, obtained
Mixed solution；
By 93.5 parts of the mixed solution and isopropanol, 5 parts of glycerine mixes, to obtain the final product.
Present invention also offers the ear drug regimen prepared by above-mentioned ear pharmaceutical composition or above-mentioned preparation method
Application of the thing in the volatilization ear of preparation in moisture, antibacterial medicines.
Present invention also offers a kind of ear pharmaceutical preparation, the ear pharmaceutical preparation by above-mentioned ear pharmaceutical composition and
Pharmaceutically acceptable auxiliary material is made.
Preferably, the ear is spray, liniment, gelling agent or paste with pharmaceutical preparation agent formulation.
Preferably, the ear is spray with pharmaceutical preparation agent formulation.
Part of the present invention is in gram.
Isopropanol：There is volatile organic reagent for one kind, can rapidly volatilize in atmosphere, pass through the volatility of itself
Moisture is taken away, so as to reach the volatilization effect of moisture in ear.Meanwhile isopropanol has bactericidal effect, what can have kill golden yellow
The correlation mushroom such as staphylococcus, Candida albicans and Escherichia coli, plays ear's disinfection.Isopropanol is to skin at the same time
Irritation is relatively low, will not produce injury to duct and eardrum.
Glycerine：There is moisturizing, duct can be protected, make duct inner skin will not after moisture evaporation is complete in duct
Overdrying, moistens duct inner skin, makes in duct water tariff collection in the range of a normal moisture.
Allantoin：With cell growth is promoted, accelerate the physiological function such as wound healing, cutin-softening albumen, be skin wound
The good consolidant and antiulcer agents of wound, can be used as alleviating and treat xerodermia, scaling skin illness, skin ulcer.
Simultaneously as allantoin is a kind of amphoteric compound, many kinds of substance can be combined and form double salt, there is lucifuge, sterilization and anticorrosion, stop
Bitterly, antioxidation, can make skin keep moisture, moisten and soft.
Boric acid：With disinfection, corrosion-resistant effect, make to keep cleaning in ear, inhibit bacteria growth.
Compared with prior art, its detailed description is as follows by the application：
The present invention provides a kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation；The ear is used
Pharmaceutical composition component includes：Isopropanol, glycerine, allantoin, boric acid component are compounded according to monarch, interaction,
Firstth, moisture evaporation in ear can not only be made；Meanwhile water tariff collection can be also kept in duct to moisten in a normal moisture scope
Ear inner skin；Secondth, antibacterial, disinfection can not only be played；At the same time, moreover it is possible to inhibit bacteria growth, maintain cleaning in ear；The
Three, irritation is relatively low, avoids producing injury to duct and eardrum, and any toxic side effect is produced to human body；4th, ear medicine
Preparation is spray, liniment, gelling agent or paste, is preferably spray, safe and convenient to use quick, and thus, the present invention provides
Ear pharmaceutical composition, ear composition it is simple, reasonable mixture ratio can effectively reduce tinnitus, dysacousis, otalgia,
Otitis externa, the generation of otitis media diseases, has good market prospects.
Embodiment
In order to make those skilled in the art more fully understand technical scheme, with reference to specific embodiment pair
The present invention is described in further detail.
Part of the present invention is in gram.
Embodiment 1
A kind of ear pharmaceutical composition, in parts by weight, the ear pharmaceutical composition component include：90 parts of isopropanol,
2 parts of glycerine, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.
In parts by weight, the ear pharmaceutical composition further includes：1.4 parts of water.
The preparation method of above-mentioned ear pharmaceutical composition, the preparation method comprise the following steps：
In parts by weight, 0.04~0.07 part of boric acid is taken, 1.4 parts with water of 0.002~0.005 part of allantoin is mixed, obtained
Mixed solution；
By 90 parts of the mixed solution and isopropanol, 2 parts of glycerine mixes, to obtain the final product.
Embodiment 2
A kind of ear pharmaceutical composition, in parts by weight, the ear pharmaceutical composition component include：92 parts of isopropanol,
4 parts of glycerine, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.
In parts by weight, the ear pharmaceutical composition further includes：1.4 parts of water.
The preparation method of above-mentioned ear pharmaceutical composition, comprises the following steps：
In parts by weight, 0.04~0.07 part of boric acid is taken, 1.4~1.6 parts with water of 0.002~0.005 part of allantoin mixes,
Obtain mixed solution；
By 92~95 parts of the mixed solution and isopropanol, 4~6 parts of glycerine mixes, to obtain the final product.
Embodiment 3
A kind of ear pharmaceutical composition, in parts by weight, the ear pharmaceutical composition component include：Isopropanol 93.5
Part, 5 parts of glycerine, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.
In parts by weight, the ear pharmaceutical composition further includes：1.5 parts of water.
The preparation method of above-mentioned ear pharmaceutical composition, comprises the following steps：
In parts by weight, 0.04~0.07 part of boric acid is taken, 1.5 parts with water of 0.002~0.005 part of allantoin is mixed, obtained
Mixed solution；
By 93.5 parts of the mixed solution and isopropanol, 5 parts of glycerine mixes, to obtain the final product.
Embodiment 4
A kind of ear pharmaceutical composition, in parts by weight, the ear pharmaceutical composition component include：95 parts of isopropanol,
6 parts of glycerine, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.
In parts by weight, the ear pharmaceutical composition further includes：1.6 parts of water.
The preparation method of above-mentioned ear pharmaceutical composition, comprises the following steps：
In parts by weight, 0.04~0.07 part of boric acid is taken, 1.6 parts with water of 0.002~0.005 part of allantoin is mixed, obtained
Mixed solution；
By 95 parts of the mixed solution and isopropanol, 6 parts of glycerine mixes, to obtain the final product.
Embodiment 5
A kind of ear pharmaceutical composition, in parts by weight, the ear pharmaceutical composition component include：98 parts of isopropanol,
8 parts of glycerine, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.
In parts by weight, the ear pharmaceutical composition further includes：1.6 parts of water.
The preparation method of above-mentioned ear pharmaceutical composition, comprises the following steps：
In parts by weight, 0.04~0.07 part of boric acid is taken, 1.6 parts with water of 0.002~0.005 part of allantoin is mixed, obtained
Mixed solution；
By 98 parts of the mixed solution and isopropanol, 8 parts of glycerine mixes, to obtain the final product.
Embodiment 6
Ear is made with pharmaceutical preparation of the ear pharmaceutical composition of embodiment 1~5.
Formulation is：Spray.
It is calculated in mass percent, above-mentioned ear pharmaceutical preparation middle ear pharmaceutical composition content is 100%.
Embodiment 7
Ear pharmaceutical preparation
Ear pharmaceutical composition made from Example 1~5, adds acceptable auxiliary material in conventional pharmaceutical, mixes, according to
Conventional method, is made liniment.
Embodiment 8
Ear pharmaceutical preparation
Ear pharmaceutical composition made from Example 1~5, adds acceptable auxiliary material in conventional pharmaceutical, mixes, according to
Conventional method, is made gelling agent.
Embodiment 9
Ear pharmaceutical preparation
Ear pharmaceutical composition made from Example 1~5, adds acceptable auxiliary material in conventional pharmaceutical, mixes, according to
Conventional method, is made paste.
Embodiment 10
Physical and chemical index detection is carried out to ear pharmaceutical composition prepared by embodiment 1~5, the results are shown in Table 1.
Table 1
| Project | Index |
| Lead (in terms of pb) mg/kg≤ | 1.5 |
| Arsenic (in terms of As) mg/kg≤ | 1.0 |
| Total mercury (in terms of Hg) mg/kg≤ | 0.3 |
Testing result shows, by ear pharmaceutical composition made from preparation method provided by the invention, reduce lead,
The content of the heavy metals such as total arsenic, total mercury, the content of lead is controlled within 1.5mg/kg, and the content of total arsenic is controlled in 1.0mg/kg
Within, the content of total mercury is controlled within 0.3mg/kg, is had no toxic side effect to human body.
Embodiment 11
Acute toxicity maximum resistance test
It is maximum resistance to tested that according to embodiments of the present invention 6~10 ears prepared carry out animal with pharmaceutical preparation acute toxicity
Test, the day maximal tolerance dose to mouse administration is 420 times of adult's consumption per day, does not observe that the present invention is prepared under this dosage
The toxic reaction of the preparation arrived.
Embodiment 12
Volatilization experiment detection
1. experimental method：
1.1 experimental groups 1~5：
Experimental group 1~5：It is respectively adopted in embodiment 6 and ear medicine is made by the ear pharmaceutical composition of embodiment 1~5
Spray.
Every group takes pan paper one to open respectively, weighs its weight and records, and the spray 1ml ear medicament spraying agents of sprinkling one are in weighing
On paper, it is positioned at once on one thousandth electronic balance and records initial weight, thereafter every one minute record once, until weight
Untill no longer changing.It is repeated twice and is averaged.Weigh temperature twice and humidity should be identical.
1.2 control groups 1：Take pan paper one to open, weigh its weight and record, the spray 0.05ml water of sprinkling one on pan paper,
Weigh its weight and record, then spray in a spray 0.05ml embodiments 6 and ear medication is made by the ear pharmaceutical composition of embodiment 3
Composition spray is positioned on one thousandth electronic balance on pan paper and records initial weight at once, remembers every one minute thereafter
Record once, untill weight no longer changes.It is repeated twice and is averaged.Weigh temperature twice and humidity should be identical.
1.3 control groups 2：Take pan paper one to open, weigh its weight and record, the spray 0.05ml water of sprinkling one on pan paper,
It is positioned at once on one thousandth electronic balance and records initial weight, thereafter every one minute record once, until weight is no longer
Untill change.It is repeated twice and is averaged.Weigh temperature twice and humidity should be identical.
3. all data of statistical procedures are analyzed using SAS.
4. experimental result：It is shown in Table 2
The volatilization experimental result of table 2
As shown in Table 2, ear pharmaceutical composition provided by the invention is added, its moisture evaporation speed is far longer than moisture and exists
The evaporation rate in ear pharmaceutical composition provided by the invention is not added.Ear pharmaceutical composition provided by the invention can make
Moisture evaporation in ear, and evaporation rate is fast, in parts by weight, the ear pharmaceutical composition component includes：Isopropanol 90~98
Part, 2~8 parts of glycerine, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.Preferably, in parts by weight, the ear
Pharmaceutical composition includes：92~95 parts of isopropanol, 4~6 parts of glycerine, 0.04~0.07 part of boric acid, allantoin 0.002~
0.005 part.It is furthermore preferred that in parts by weight, the ear pharmaceutical composition includes：93.5 parts of isopropanol, 5 parts of glycerine, boric acid
0.04~0.07 part, 0.002~0.005 part of allantoin.In parts by weight, the ear pharmaceutical composition further includes：Water 1.4~
1.6 part.Preferably, in parts by weight, the ear pharmaceutical composition further includes：1.5 parts of water.
Embodiment 13
Bacteriostatic experiment detects
1. test material
1.1 experiment microorganism fungus kinds
Bacterium：Escherichia coli (ATCC 8739 or 8099), staphylococcus aureus (ATCC 6538)；
Saccharomycete：Candida albicans (ATCC 10231).
1.2 test medicine
Test group A~E：The ear pharmaceutical preparation as made from the ear pharmaceutical composition of embodiment 1~5 in embodiment 6；
Neutralizer：Neutralizer qualification test is quantified by suspension.
2. operation sequence
2.1 take the generation nutrient agar slopes fresh cultured thing (18-24h) of each the 3rd generation of strain~14, with 0.03mol/L phosphoric acid
Salt buffer (PBS) is washed down, is diluted to bacteria containing amount as 5 × 107Cfu/ml~5 × 108The bacteria suspension of cfu/ml.
2.2 draw 10.0ml ears respectively from test group A~E each groups is added on pharmaceutical preparation in three sterilizing test tubes, altogether
158 sterilizing test tubes, are placed in 20 DEG C~25 DEG C water-bath 5min.
2.3 are separately added into 0.1ml bacteria suspensions in each sterilizing test tubes, obtain bacterium medicine mixed liquor, make final each sterilizing test tubes
Middle bacterium medicine mixed liquor bacteria containing amount is 5 × 105Cfu/ml~5 × 106Cfu/ml, mixes, and starts timing.
2.4 press 4 different action times in table 3 respectively, take the 1.0ml bacterium medicines mixed liquor in each sterilizing test tubes to move into
In 9.0ml neutralizers, mix, neutralized.
In 2.5 and after 10min, draw 1.0ml and be inoculated with, strain is inoculated with for bacterium using nutrient agar, bacterium
Kind is inoculated with for saccharomycete using husky fort agar medium, respectively at 35 DEG C~37 DEG C culture 48h (bacterium) or 72h (ferment after inoculation
Female bacterium), make count plate, take its average value.
2.6
Positive control：Sample is replaced with 0.03mol/L PBS, in same way as described above plus bacterium carries out count plate as sun
Property control.
Negative control：Take and nutrient agar, Sha Bao are inoculated in 0.03mol/LPBS, each 1.0ml of neutralizer respectively
Agar medium is as negative control, asepsis growth.
2.7 are calculated the killing rate of every kind of each action time point of bacterium by following equation：
3. all data of statistical procedures are analyzed using SAS.
4. experimental result：It is shown in Table 3.
3 bacteriostatic experiment result of table
As shown in Table 3, ear pharmaceutical composition provided by the invention, ear pharmaceutical preparation, can effective sterilization, sterilization speed
Degree is fast, and has fungistatic effect.Thus, ear pharmaceutical composition provided by the invention, ear pharmaceutical preparation can not only play suppression
Bacterium, disinfection；At the same time, moreover it is possible to inhibit bacteria growth, maintain cleaning in ear
It the above is only the preferred embodiment of the present invention, it is noted that above-mentioned preferred embodiment is not construed as pair
The limitation of the present invention, protection scope of the present invention should be subject to claim limited range.For the art
For those of ordinary skill, without departing from the spirit and scope of the present invention, some improvements and modifications can also be made, these change
Protection scope of the present invention is also should be regarded as into retouching.
Claims (10)
1. a kind of ear pharmaceutical composition, it is characterised in that in parts by weight, the ear pharmaceutical composition component includes：It is different
90~98 parts of propyl alcohol, 2~8 parts of glycerine, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.
2. ear pharmaceutical composition according to claim 1, it is characterised in that in parts by weight, the ear drug regimen
Thing includes：92~95 parts of isopropanol, 4~6 parts of glycerine, 0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.
3. ear pharmaceutical composition according to claim 1, it is characterised in that in parts by weight, the ear drug regimen
Thing further includes：1.4~1.6 parts of water.
4. ear pharmaceutical composition according to claim 3, it is characterised in that in parts by weight, the ear drug regimen
Thing further includes：1.5 parts of water.
5. a kind of preparation method of ear pharmaceutical composition, it is characterised in that comprise the following steps：Take ear pharmaceutical composition group
Divide mixing, to obtain the final product；In parts by weight, the ear pharmaceutical composition component includes：90~98 parts of isopropanol, 2~8 parts of glycerine,
0.04~0.07 part of boric acid, 0.002~0.005 part of allantoin.
6. preparation method according to claim 5, it is characterised in that in parts by weight, the ear pharmaceutical composition is also
Including：1.4~1.6 parts of water.
7. preparation method according to claim 6, it is characterised in that the preparation method comprises the following steps：
In parts by weight, 0.04~0.07 part of boric acid is taken, 1.4~1.6 parts with water of 0.002~0.005 part of allantoin is mixed, obtained
Mixed solution；
By 90~98 parts of the mixed solution and isopropanol, 2~8 parts of glycerine mixes, to obtain the final product.
8. according to Claims 1 to 4 any one of them ear pharmaceutical composition or claim 5~7 any one of them system
Application of the ear pharmaceutical composition in the volatilization ear of preparation in moisture, antibacterial medicines prepared by Preparation Method.
9. a kind of ear pharmaceutical preparation, it is characterised in that the ear pharmaceutical preparation is by Claims 1 to 4 any one of them
Ear pharmaceutical composition and pharmaceutically acceptable auxiliary material are made.
10. ear pharmaceutical preparation according to claim 9, it is characterised in that the ear is spraying with medicament form of pharmaceutical preparation
Agent, liniment, gelling agent or paste.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711402613.8A CN107970257A (en) | 2017-12-22 | 2017-12-22 | A kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711402613.8A CN107970257A (en) | 2017-12-22 | 2017-12-22 | A kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107970257A true CN107970257A (en) | 2018-05-01 |
Family
ID=62007497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711402613.8A Pending CN107970257A (en) | 2017-12-22 | 2017-12-22 | A kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107970257A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125255A (en) * | 2018-09-30 | 2019-01-04 | 天津梅花生物医药科技有限公司 | A kind of auristilla |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327382A (en) * | 1998-12-23 | 2001-12-19 | 伊迪亚股份公司 | Improved formulation for topical non-invasive application in vivo |
| CN106176758A (en) * | 2016-06-17 | 2016-12-07 | 北京梅尔森医药技术开发有限公司 | A kind of externally-applied medicinal composition |
-
2017
- 2017-12-22 CN CN201711402613.8A patent/CN107970257A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327382A (en) * | 1998-12-23 | 2001-12-19 | 伊迪亚股份公司 | Improved formulation for topical non-invasive application in vivo |
| CN106176758A (en) * | 2016-06-17 | 2016-12-07 | 北京梅尔森医药技术开发有限公司 | A kind of externally-applied medicinal composition |
Non-Patent Citations (2)
| Title |
|---|
| 杭娟: "硼酸甘油滴耳液质量标准提高研究", 《解放军药学学报》 * |
| 顾文珍: "尿囊素的作用及其临床应用", 《新药与临床》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125255A (en) * | 2018-09-30 | 2019-01-04 | 天津梅花生物医药科技有限公司 | A kind of auristilla |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104274490B (en) | Bactericidal composition including source of silver ions and menthol and application thereof | |
| CN105055642A (en) | Compound guanidine disinfectant and preparation method of compound guanidine disinfectant | |
| CN109316536A (en) | A kind of skin mucosa disinfecting agent and preparation method thereof | |
| CN105031609B (en) | The disinfectant and its preparation and use of the Cbf-14 containing antibacterial peptide | |
| CN108553355A (en) | A kind of compound houttuynin oral bacteriostasis fresh and cool spray and preparation method thereof | |
| CN109077945A (en) | Combined bacteriostat with lysozyme for cosmetics | |
| CN113995744B (en) | Composition and antibacterial application thereof | |
| CN106234388B (en) | A kind of composition pesticide of alkene containing benzo fluorine bacterium azoles and jamaicin | |
| CN112891372B (en) | Hydrogen peroxide and nano-silver compound hand disinfectant and preparation method thereof | |
| CN100431617C (en) | New use of orange essence in sterilizing | |
| CN107970257A (en) | A kind of ear pharmaceutical composition, preparation method and applications and ear pharmaceutical preparation | |
| CN104524559A (en) | Lysostaphic complex enzyme oral cavity disinfectant and preparation method thereof | |
| CN1524587A (en) | Nursing wet towel using tea plant oil as antibacterial and fungistatic agent and production method thereof | |
| CN105028423B (en) | A kind of Pesticidal combination containing ethyl pleocidin and pyridaben and purposes | |
| CN107198769A (en) | Oral disinfecting spray and preparation method thereof | |
| CN108210990A (en) | It is a kind of using graphene oxide as the new liquid adhesive bandage of antibacterial components | |
| CN111500490A (en) | Microbial type bacteriostatic and odor-removing preparation as well as preparation method and application thereof | |
| CN101491245A (en) | Disinfection preparation containing forest frog antibacterial peptide and preparation method and use thereof | |
| CN106581051A (en) | Nano microemulsion iodine and preparation method thereof | |
| CN101077362B (en) | Plant-type skin mucosa disinfecting agent | |
| CN102836247B (en) | Tangerine extract composition for feminite care | |
| CN106420938B (en) | A kind of Chinese medicine composition and preparation method thereof for treating oral inflammation and pharyngitis | |
| CN115443996A (en) | Application of citral | |
| CN108079050A (en) | Herbal skin bacteria inhibiting composition and preparation method and application | |
| CN110433117A (en) | Mouthwash and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20181130 Address after: 611700 Second Floor, Building No. 2, 269 Gangtongbei Third Road, Chengdu Modern Industrial Port Area, Pidu District, Chengdu City, Sichuan Province Applicant after: Chengdu Bo Chuang Bicheng Biotechnology Co., Ltd. Address before: 610041 10 10, Keyuan South Road, hi tech Zone, Chengdu, Sichuan Applicant before: Chengdu Bochuang Bicheng Medical Technology Co., Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180501 |